论文部分内容阅读
Objectives Toevaluate the effect of dimercaptosuccinic acid (DMSA)-coated superparamagnetic iron oxide (γ-Fe2O3@DMSA) bearing 2-deoxy-D-glucose (2-DG) ligands for the targeting of high glucose metabolism tumor. Methods The γ-Fe2O3@DMSA and 2-DG conjugated γ-Fe2O3@DMSA (γ-Fe2O3@DMSA-DG) were prepared. The glucose metabolic rate of MDA-MB-231 and MCF-7 breast cancer cells and human mammary epithelial cells (HMEpiC) were assessed by Glucose oxidase peroxidase assay. In vitro cellular uptake of γ-Fe2O3@DMSA or γ-Fe2O3@DMSA-DG was measured by Prussian blue staining, Ultraviolet colorimetric assay, and Magnetic resonance imaging (MRI). In vivo distribution was studied by MRI and Prussian blue staining in human MDA-MB-231 xenografts. Results Glucose metabolic rate of MDA-MB-231 cells was the highest, and that of HMEpiC was the lowest. In vitro, MDA-MB-231 and MCF-7 cells uptaked γ-Fe2O3@DMSA-DG significantly in 2 hours, and could be competitively inhibited by glucose, and the former cells uptaked more than the latter cells significantly, but there were no obvious uptake of γ-Fe2O3@DMSA. However HMEpiC couldnt uptake any particles. In vivo, in addition to liver, γ-Fe2O3@DMSA-DG could be detected in tumor 6 h-48 h after injection, but γ-Fe2O3@DMSA was nearly undetectable in tumor. Conclusions 2-DG coated γ-Fe2O3@DMSA improved tumor targeting of γ-Fe2O3@DMSA, which can be assessed by 1.5 T MR.